Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OptimizeRxOPRX +5.04%59 Debt-to-Equity is 0.18 as of Mar. 2026, which is 1700% above its 10-year median of 0.01. GuruFocus rates OPRX with a GF Score™ of 59/100 and a GF Value™ of $12.88 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 556 Healthcare Providers & Services companies, OptimizeRx ranks better than 70.5% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for OptimizeRx's Debt-to-Equity or its related term are showing as below:
OPRX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.31
Current: 0.18
During the past 13 years, the highest Debt-to-Equity Ratio of OptimizeRx was 0.31. The lowest was 0.00. And the median was 0.01.
OPRX's Debt-to-Equity is ranked better than 70.5% of 556
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs OPRX: 0.18
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
OptimizeRx Debt-to-Equity Related Terms
OptimizeRx Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for OptimizeRx's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, OptimizeRx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptimizeRx Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where OptimizeRx's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptimizeRx (OPRX) has a Debt-to-Equity of 0.18 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OptimizeRx and its competitors. This is 1700% above median its historical median of 0.01. According to the industry distribution chart, OptimizeRx ranks #164 out of 556 companies in the Healthcare Providers & Services industry, placing it in the top 29.5%.
Is OptimizeRx's Debt-to-Equity too high?
OptimizeRx's current Debt-to-Equity of 0.18 is 1700% above median its 10-year median of 0.01. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. OptimizeRx's value of 0.18 is 57.1% below this industry median. Based on the distribution chart, OptimizeRx ranks #164 out of 556 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, OptimizeRx has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does OptimizeRx's Debt-to-Equity compare to CCLD and HCAT?
According to the Healthcare Providers & Services industry distribution chart, OptimizeRx ranks #164 out of 556 companies for Debt-to-Equity. This puts OptimizeRx in the upper half of its industry. The industry median Debt-to-Equity is 0.42. OptimizeRx's value of 0.18 is 57.1% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.42, OptimizeRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OptimizeRx's current Debt-to-Equity of 0.18 is 57.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OptimizeRx and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OptimizeRx's current Debt-to-Equity is 0.18, which is 1700% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptimizeRx stock overvalued right now?
Based on GuruFocus' analysis, OptimizeRx (OPRX) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.88, compared to a current price of $7.08 — trading 45.1% below its estimated fair value. The current Debt-to-Equity is 0.18, which is 1700% above median its 10-year median of 0.01 and 57.1% below the Healthcare Providers & Services industry median of 0.42. OptimizeRx's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For OptimizeRx (OPRX), the current Debt-to-Equity is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OptimizeRx (OPRX) Overvalued in 2026?
Based on GuruFocus' analysis, OptimizeRx stock appears to be undervalued.
The current stock price of $7.08 is trading 45.1% below its estimated GF Value™ of $12.88.
GuruFocus considers OptimizeRx to be Significantly Undervalued.
Key valuation signals for OPRX:
Debt-to-Equity: 0.18 (1700% above median its 10-year median of 0.01)
GF Value™: $12.88 vs. price of $7.08 (45.1% below fair value)
Industry Position: 57.1% below the Healthcare Providers & Services median (#164 of 556)
No single metric tells the full story. See the OPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
59GF Score
Get the complete analysis for OPRX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPRX has been successfully added to your 
